WallStSmart

Caring Brands, Inc. Common Stock (CABR)vsZoetis Inc (ZTS)

VS

CABR

Caring Brands, Inc. Common Stock

NASDAQ

$1.30

0.00%

HEALTHCARE · Cap: $12.34M

ZTS

Zoetis Inc

NYSE

$71.33

-0.10%

HEALTHCARE · Cap: $29.50B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Zoetis Inc generates 821829063% more annual revenue ($9.53B vs $1,159). ZTS leads profitability with a 27.7% profit margin vs 0.0%. ZTS earns a higher WallStSmart Score of 58/100 (C).

CABR

Avoid

15

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 5.8
Piotroski: 5/9Altman Z: -5.82

ZTS

Buy

58

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 6.0Quality: 7.0
Piotroski: 4/9Altman Z: 3.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CABR.

ZTSUndervalued (+11.0%)

Margin of Safety

+11.0%

Fair Value

$144.59

Current Price

$71.33

$73.26 discount

UndervaluedFair: $144.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CABR0 strengths · Avg: 0/10

No standout strengths identified

ZTS5 strengths · Avg: 9.8/10
P/E RatioValuation
11.7x10/10

Attractively priced relative to earnings

Return on EquityProfitability
83.1%10/10

Every $100 of equity generates 83 in profit

Operating MarginProfitability
40.7%10/10

Strong operational efficiency at 40.7%

Altman Z-ScoreHealth
3.1410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
27.7%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

CABR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$12.34M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-217.1%2/10

ROE of -217.1% — below average capital efficiency

ZTS4 concerns · Avg: 3.0/10
Price/BookValuation
9.1x4/10

Trading at 9.1x book value

EPS GrowthGrowth
1.2%4/10

1.2% earnings growth

PEG RatioValuation
6.642/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : CABR

CABR has a balanced fundamental profile.

Bull Case : ZTS

The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.

Bear Case : CABR

The primary concerns for CABR are EPS Growth, Market Cap, Profit Margin.

Bear Case : ZTS

The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.

Key Dynamics to Monitor

CABR profiles as a value stock while ZTS is a declining play — different risk/reward profiles.

ZTS is growing revenue faster at -0.2% — sustainability is the question.

ZTS generates stronger free cash flow (538M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZTS scores higher overall (58/100 vs 15/100), backed by strong 27.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Caring Brands, Inc. Common Stock

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Caring Brands, Inc., a wellness consumer products company, provides over-the-counter and cosmetic consumer products. The company is headquartered in Fort Pierce, Florida.

Zoetis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.

Visit Website →

Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks

CABR vs TAKCABR vs TEVACABR vs HLNCABR vs UTHRCABR vs VTRSZTS vs TAKZTS vs TEVAZTS vs HLNZTS vs UTHRZTS vs VTRS

Want to dig deeper into these stocks?

Full CABR Analysis →Full ZTS Analysis →